Eckert & Ziegler

(IN BRIEF) Eckert & Ziegler successfully hosted the 3rd annual Boston Radionuclide Theranostics Forum, bringing together industry leaders to discuss radionuclide theranostics’ role in transforming precision oncology. The event featured expert presentations on advancements in radiopharmaceuticals, clinical development challenges, and … Read the full press release →

(IN BRIEF) Eckert & Ziegler SE has been awarded the “Best Managed Companies Award” for the second time, a prestigious recognition celebrating excellence in strategy, innovation, culture, and governance. This accolade underscores the company’s continued leadership in supplying isotopes for … Read the full press release →

(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic … Read the full press release →

(IN BRIEF) Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have announced a significant global supply agreement aimed at supporting AtomVie’s radiopharmaceutical manufacturing efforts. Under this agreement, Eckert & Ziegler will provide its high-grade non-carrier added Lutetium-177 chloride (Theralugand®) … Read the full press release →